PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33015417-6	2020	Selective activation of HIF-2alpha can be achieved with drugs that: 1) inhibit isoform-selective prolyl hydroxylases (e.g., cobalt chloride and roxadustat); or 2) promote the actions of the redox sensor, sirtuin-1 (e.g., sodium-glucose cotransporter 2 inhibitors).	roxadustat	144-154	endothelial PAS domain protein 1	Homo sapiens	24-34	
33011826-7	2020	Roxadustat stabilized HIF-1alpha and HIF-2alpha, suppressed cell proliferation, inhibited CD4+ T-cell differentiation into Th1 and Th17 subsets, while it favored differentiation towards Th2, Treg and Tfh.	roxadustat	0-10	endothelial PAS domain protein 1	Homo sapiens	37-47	
32142369-9	2020	The PHD2 (prolyl hydroxylase domain-containing protein 2) inhibitor FG-4592 significantly increased NAMPT promoter activity and protein expression in an HIF-2alpha-dependent manner.	roxadustat	68-75	endothelial PAS domain protein 1	Homo sapiens	153-163	
32380083-2	2020	Prolyl hydroxylase (PHD) inhibitors, such as roxadustat, can stabilize hypoxia-inducible factor (HIF)-2alpha and induce erythropoietin (EPO) production under normal conditions.	roxadustat	45-55	endothelial PAS domain protein 1	Homo sapiens	71-108